In its latest move, Google has made Gemini 2.0, its most powerful suite of AI models, available to the general public.

Why are CRISPR companies not OK? Will Robert F. Kennedy Jr. keep his promises if he's confirmed to lead the Department of ...

The pharmaceutical company plans to cut $2 billion in annual expenses by the end of 2027 through “operational efficiencies ...

With the addition of Casgevy, Children’s Hospital Los Angeles now offers two gene therapies for sickle cell, the first being Lyfgenia.

CenExel, a leading network of clinical research sites, proudly congratulates and announces its role in supporting Vertex Pharmaceuticals’ clinical studies that led to the FDA approval of JOURNAVX™ ...

The flood of AI news from Google comes in the wake of the launch of DeepSeek, the breakthrough Chinese AI tool that's been ...

Flash-Lite 2 can generate captions for around 40,000 unique images at a cost of less than a dollar on Google AI Studio’s paid ...

Cook Wealth LLC lowered its stake in Exxon Mobil Co. (NYSE:XOM – Free Report) by 13.4% in the 4th quarter, ...

Willis Investment Counsel grew its holdings in shares of Exxon Mobil Co. (NYSE:XOM – Free Report) by 0.9% during the fourth ...

In an announcement on Wednesday morning, Google has officially released the Gemini 2.0 series of AI models, including Gemini ...

Journave, the first non-addictive opioid-like pain medication, was developed based on Yale research from the ’90s.

Google just dropped 4 new Gemini 2.0-series models, with some designed for coding performance and complex prompts and the ...